Key Points
- Hillstream Biopharma director Gary Stetz sold 87,851 shares on May 22 at an average price of $3.42, totaling about $300,450. The sale reduced his position by 37.46% and was disclosed in an SEC filing.
- CNTN shares were trading down 1.8%, opening at $3.23. The stock has a market cap of $225.49 million and has traded between $1.08 and $9.08 over the past 12 months.
- The company reported a quarterly EPS loss of $0.23 in its latest earnings release. Analyst sentiment remains weak, with a consensus rating of Sell.
Hillstream Biopharma Inc. (NASDAQ:CNTN - Get Free Report) Director Gary Stetz sold 12,500 shares of the company's stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $3.47, for a total value of $43,375.00. Following the completion of the sale, the director owned 134,175 shares of the company's stock, valued at approximately $465,587.25. This trade represents a 8.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Hillstream Biopharma Stock Performance
Shares of Hillstream Biopharma stock opened at $3.23 on Thursday. The firm has a market capitalization of $225.47 million, a price-to-earnings ratio of -2.81 and a beta of 1.44. The company has a fifty day moving average price of $3.33. Hillstream Biopharma Inc. has a fifty-two week low of $1.08 and a fifty-two week high of $9.08.
Hillstream Biopharma (NASDAQ:CNTN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.23) earnings per share for the quarter.
Analyst Upgrades and Downgrades
CNTN has been the subject of several research analyst reports. Weiss Ratings lowered Hillstream Biopharma from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, May 15th. Wall Street Zen raised Hillstream Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, May 16th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of "Sell".
View Our Latest Stock Analysis on CNTN
About Hillstream Biopharma
(
Get Free Report)
Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
